N/A N=31 Effect of Spice Consumption on the Microbiome
Microbiota
Primary: Change in Microbial Phylum Abundance (% of Total) Between Spice and Placebo — 65.1; 65.9; 58.7; 70.1 percentage of total bacteria — p=0.033
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,405 A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
Type 1 Diabetes Mellitus (T1DM) · High Level of Sugar (Glucose) in the Blood
Primary: Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization — 15.2; 28.6…
N/A N=34 Feasibility of a Wearable-enabled Intervention for Promoting Physical Activity in People Knee OA
Knee Osteoarthritis · Joint Diseases
Primary: Time Spent in Moderate-to-Vigorous Physical Activity (MVPA) — 41.3; 66.5; 64.2; 56.0 Minutes per day — p=0.02
N/A N=5,038 Right For Me: Birth Control Decisions Made Easier
Contraception
Primary: Shared Decision-making About Contraceptive Methods — 165; 272; 222; 190 Participants — p=0.80
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
Phase 2 N=220 A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Rheumatoid Arthritis
Primary: Maximum Serum Concentration (Cmax) of Rituximab — 453; 422; 430 micrograms per milliliter
Phase 2 N=60 IINB vs. QLB for Elective Open Inguinal Herniorrhaphy
Nerve Block · Herniorrhaphy · Regional Anesthesia
Primary: Post-operative Verbal Pain Score With Movement — 5.10; 5.03 score on a scale
N/A N=57 Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction
Rupture of Anterior Cruciate Ligament · Tear of Anterior Cruciate Ligament
Primary: Subjective Postoperative Pain Scores After Preoperative Femoral Nerve Block Plus Postoperative Continuous Adductor Canal Nerve Catheter Compared to Preoperative Femoral…
N/A N=3,063 Predicting Persistent Postconcussive Problems in Pediatrics (5P)
Concussions · PCS
Primary: Count of Children Who Have Persistent Post-concussive Symptoms (PCS) at One-month Follow-up. — 510; 291 Participants
Phase 2 N=73 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Ganglioneuroblastoma · Recurrent Neuroblastoma
Primary: Percentage of Randomized Patients Who Are Responders — 5.6; 52.9 Percentage of patients
Phase 2 N=59 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Metastatic Differentiated Thyroid Cancer · Metastatic Poorly Differentiated Thyroid Cancer · Metastatic Anaplastic Thyroid Cancer
Primary: To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma. — 0; 16; 22; 1…
Phase 1 N=36 Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Number of Subjects With Anti-V1V2 Total Immunoglobulin G (IgG) Binding Antibody Multiplex Assay (BAMA) Response Call — 25; 15; 8; 20 Participants
N/A N=46 Treatment of Chronic Stroke With AMES + EMG Biofeedback
Stroke · Plegia · Paresis
Primary: Box and Blocks Test — 0.0; 0.5 Number of blocks moved — p=<0.005
Phase 1 N=84 Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents
Tuberculosis
Primary: Number of Participants With Adverse Events — 22; 20; 24; 10 participants
N/A N=40 Efficacy of Preoperative Pectoral Nerve Block for Intraoperative Opioid Sparing Effect and Postoperative Analgesia
Breast Cancer
Primary: Intraoperative Remifentanil Consumption — 6.75; 10.12 μg/kg/h